Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1 2

Status

Completed 5Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Carcinoma, Hepatocellular 6Colorectal Neoplasms 4Neoplasms 3Uterine Cervical Neoplasms 2Neoplasm Metastasis 2Liver Neoplasms 2Solid Tumors 1Sarcoma 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Ovarian Neoplasms 1Gastrointestinal Neoplasms 1Endometrial Adenocarcinoma 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Advanced Hepatocellular Carcinoma (HCC) 1Adenocarcinoma Of Esophagus 1Acrocephalosyndactylia 1

Interventions

Sorafenib 202lenvatinib 129Bevacizumab 125Nivolumab 84pembrolizumab 72atezolizumab 72Radiosurgery 71durvalumab 63Oxaliplatin 59sintilimab 57Fluorouracil 54Doxorubicin 44tislelizumab 43apatinib 42Leucovorin 40tremelimumab 37Radiofrequency Ablation 37camrelizumab 36Radiotherapy 36Magnetic Resonance Spectroscopy 32Capecitabine 30regorafenib 29Folfox protocol 29Cisplatin 28Hepatectomy 26Gemcitabine 26Cyclophosphamide 26cabozantinib 25Ipilimumab 25toripalimab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Hepatocellular × brivanib × Clear all
NCT00355238 2023-12-01

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Bristol-Myers Squibb

Phase 2 Completed
137 enrolled 20 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT00908752 2019-12-02

BRISK TA

Bristol-Myers Squibb

Phase 3 Completed
734 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03516071 2019-09-04

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Zai Lab (Hong Kong), Ltd.

Phase 2 Completed
90 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01108705 2015-10-12

BRISK-APS

Bristol-Myers Squibb

Phase 3 Terminated
87 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT01540461 2014-07-08

Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

Bristol-Myers Squibb

Phase 1 Completed
17 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00437424 2011-05-04

A Study of Brivanib (BMS-582664) in Patients With Liver Cancer and Mild, Moderate or Severe Liver Dysfunction

Bristol-Myers Squibb

Phase 1 Completed
24 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡